Alt Text

Access Serology Test: Fighting the COVID-19 Pandemic

We are providing rapid, highly accurate COVID diagnostics to those who need it most.

In partnership with QIAGEN®, Ellume has accelerated the development of a rapid, reliable COVID test to support the global response to the coronavirus pandemic. The QIAGEN Access Anti-SARS-CoV-2 Total, is a high-performance serological test which detects antibodies in people who have been exposed to SARS-CoV-2.

The test has received an Emergency Use Authorization (EUA) from the US FDA, with CE-IVD marking anticipated in the coming weeks.

Sensitivity of 100% (CI 88.43–100.00%)
Specificity of 100% (CI 95.20–100.00%)

Alt Text

Key Features

● Early positive results from 3 minutes

● Simple testing process

● Minimal training requirements

● Single patient visit

● Objective automated test result

● No calibration or maintenance required

● No cold chain required

● No continuous power supply required

● No computer access required

Coronavirus: The Facts

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. COVID-19 is a respiratory illness primarily spread from person to person. COVID-19 symptoms can range from mild (or no symptoms) to severe illness. There are currently more than 21 million* confirmed cases globally with >775,000 deaths*. With no specific vaccines or treatments currently available for COVID-19, rapid diagnosis is pivotal to minimising transmission.

* Last update: 20 August 2020 –

Sign up for our Newsletter

* indicates required